NYSEAMERICAN:AIM AIM ImmunoTech (AIM) Stock Price, News & Analysis $0.16 0.00 (-2.92%) Closing price 10/23/2026 04:10 PM EasternExtended Trading$0.16 +0.01 (+4.93%) As of 10/23/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About AIM ImmunoTech Stock (NYSEAMERICAN:AIM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AIM ImmunoTech alerts:Sign Up Key Stats Today's Range$0.15▼$0.1750-Day Range$0.16▼$0.2652-Week Range$0.15▼$2.88Volume913,317 shsAverage Volume837,170 shsMarket Capitalization$4.76 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingModerate Buy Company Overview AIM ImmunoTech Inc. is a clinical-stage immuno-pharmaceutical company focused on developing therapies that activate and regulate the immune system. The company’s research programs target cancer, viral diseases and other conditions in which immune-system activity may play a role in disease progression or treatment response. AIM’s principal investigational product is Ampligen (rintatolimod), a double-stranded RNA-based immune modulator designed to stimulate antiviral and antitumor immune responses. Ampligen has been studied in conditions including myalgic encephalomyelitis/chronic fatigue syndrome, various cancers and viral infections. It remains an investigational therapy and has not received broad U.S. marketing approval. The company also markets Alferon N Injection, a natural human leukocyte interferon product approved in the United States for the treatment of refractory or recurring external genital warts in adults. AIM ImmunoTech was formerly known as Hemispherx Biopharma and adopted its current name in 2019. The company is headquartered in Ocala, Florida, and is led by Chief Executive Officer Thomas K. Equels. Its activities include clinical development, regulatory work and collaborations intended to advance its immune-modulating product candidates in the United States and international markets.AI Generated. May Contain Errors. Read More AIM ImmunoTech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreAIM MarketRank™: 3.793427230045 of 5 starsAIM ImmunoTech scored higher than 76% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAIM ImmunoTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.Upside PotentialAIM ImmunoTech has a consensus price target of $9.00, representing about 5,658.2% upside from its current price of $0.16.Amount of Analyst CoverageAIM ImmunoTech has received no research coverage in the past 90 days.Read more about AIM ImmunoTech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AIM ImmunoTech are expected to grow in the coming year, from ($0.78) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AIM ImmunoTech is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AIM ImmunoTech is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.66% of the float of AIM ImmunoTech has been sold short.Short Interest Ratio / Days to CoverAIM ImmunoTech has a short interest ratio ("days to cover") of 0.75, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AIM ImmunoTech has recently decreased by 49.11%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAIM ImmunoTech does not currently pay a dividend.Dividend GrowthAIM ImmunoTech does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentAIM ImmunoTech has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for AIM ImmunoTech this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for AIM on MarketBeat in the last 30 days. This is a decrease of -74% compared to the previous 30 days.MarketBeat Follows4 people have added AIM ImmunoTech to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership3.0 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $18,488.00 in company stock, which represents 0.3886% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, AIM ImmunoTech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $18,488.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders0.82% of the stock of AIM ImmunoTech is held by insiders.Percentage Held by Institutions12.02% of the stock of AIM ImmunoTech is held by institutions.Read more about AIM ImmunoTech's insider trading history. Receive AIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AIM Stock News HeadlinesAIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdaysOctober 7, 2026 | finance.yahoo.comAIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdaysOctober 7, 2026 | globenewswire.comBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.October 25 at 1:00 AM | Decentralized Masters (Ad)Aim Immunotech Inc. Highlights Recent Media Coverage of Ampligen?S Broad-Spectrum Antiviral and Biodefense PotentialOctober 6, 2026 | marketscreener.comMAIM ImmunoTech Highlights Recent Media Coverage of Ampligen's Broad-Spectrum Antiviral and Biodefense PotentialOctober 6, 2026 | marketscreener.comMAIM ImmunoTech Highlights Ampligen's Broad-Spectrum Antiviral PotentialOctober 5, 2026 | rttnews.comAIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense PotentialOctober 5, 2026 | markets.businessinsider.comAIM ImmunoTech Highlights Recent Media Coverage of Ampligen's® Broad-Spectrum Antiviral and Biodefense PotentialOctober 5, 2026 | globenewswire.comSee More Headlines AIM Stock Analysis - Frequently Asked Questions How have AIM shares performed this year? AIM ImmunoTech's stock was trading at $1.1289 at the beginning of the year. Since then, AIM shares have decreased by 86.2% and is now trading at $0.1563. How were AIM ImmunoTech's earnings last quarter? AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) released its earnings results on Friday, August, 7th. The company reported ($0.43) earnings per share (EPS) for the quarter. The business had revenue of $0.03 million for the quarter. When did AIM ImmunoTech's stock split? AIM ImmunoTech's stock reverse split on Thursday, June 12th 2025.The 1-100 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of AIM ImmunoTech? Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AIM ImmunoTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that AIM ImmunoTech investors own include Tesla (TSLA), NIO (NIO), Nokia (NOK), Vaxart (VXRT), FuelCell Energy (FCEL), iBio (IBIO) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings8/07/2026Today10/25/2026AGM 202611/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:AIM Previous SymbolNYSEAMERICAN:HEB CIK946644 Webaimimmuno.com Phone(352) 448-7797Fax215-988-1739Employees21Year Founded1990Price Target and Rating Average Price Target for AIM ImmunoTech$9.00 High Price Target$9.00 Low Price Target$9.00 Potential Upside/Downside+5,658.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($24.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.96 million Net Margins-15,021.05% Pretax Margin-15,021.05% Return on EquityN/A Return on Assets-143.02% Debt Debt-to-Equity RatioN/A Current Ratio2.11 Quick Ratio2.11 Sales & Book Value Annual Sales$90 thousand Price / Sales52.86 Cash FlowN/A Price / Cash FlowN/A Book Value($2.99) per share Price / Book-0.05Miscellaneous Outstanding Shares30,440,000Free Float30,192,000Market Cap$4.76 million OptionableNot Optionable Beta1.27 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NYSEAMERICAN:AIM) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
